期刊
CHEMISTRY-A EUROPEAN JOURNAL
卷 25, 期 1, 页码 43-59出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/chem.201803174
关键词
Bioconjugation; Cysteine; Maleimide; retro-Michael
资金
- Fundacao para a Ciencia e a Tecnologia (FCT) Portugal [SFRH/BPD/102296/2014, PTDC/QEQ-QOR/1434/2014, PTDC/QEQ-MED/5512/2014, PTDC/QEQ-QOR/3644/2014, FEDER-029967, SAICT-PAC/0019/2015, PD/BD/128239/2016, UID/DTP/04138/2013]
- Fundação para a Ciência e a Tecnologia [PTDC/QEQ-MED/5512/2014, PTDC/QEQ-QOR/3644/2014, PTDC/QEQ-QOR/1434/2014, PD/BD/128239/2016, SFRH/BPD/102296/2014] Funding Source: FCT
Maleimide chemistry stands out in the bioconjugation toolbox by virtue of its synthetic accessibility, excellent reactivity, and practicability. The second-generation of clinically approved antibody-drug conjugates (ADC) and much of the current ADC pipeline in clinical trials contain the maleimide linkage. However, thiosuccinimide linkages are now known to be less robust than once thought, and ergo, are correlated with suboptimal pharmacodynamics, pharmacokinetics, and safety profiles in some ADC constructs. Rational design of novel generations of maleimides and maleimide-type reagents have been reported to address the shortcomings of classical maleimides, allowing for the formation of robust bioconjugate linkages. This review highlights the main strategies for rational reagent design that have allowed irreversible bioconjugations in cysteines, reversible labelling strategies and disulfide re-bridging.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据